Return on Assets (Quarterly)

Return on Assets: An indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Calculated as: Income from Continuing Operations / Total Assets

Phathom Pharmaceuticals, Inc. (PHAT) had Return on Assets of -12.47% for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$49.50M
Net Income	$-29.97M
Cost of Goods Sold	$6.19M
Gross Profit	$43.31M
Operating Expenses	$64.78M
Operating Income	$-15.27M
Non-Operating Income/Expense	$-14.70M
Pre-Tax Income	$-29.97M
Normalized Pre-Tax Income	$-29.97M
Income after Taxes	$-29.97M
Income from Continuous Operations	$-29.97M
Consolidated Net Income/Loss	$-29.97M
Normalized Income after Taxes	$-29.97M
EBIT	$-15.27M
EBITDA	$-14.34M
Weighted-Average Shares Outstanding (Basic)	73.40M
Weighted-Average Shares Outstanding (Diluted)	73.40M
Earnings per Share (EPS) (Basic)	$-0.41
Earnings per Share (EPS) (Diluted)	$-0.41
Balance Sheet Financials
Current Assets	$207.78M
Property, Plant, and Equipment	$1.16M
Long-Term Assets	$32.51M
Total Assets	$240.29M
Current Liabilities	$93.12M
Long-Term Debt	$207.09M
Long-Term Liabilities	$569.70M
Total Liabilities	$662.82M
Common Equity	$-422.53M
Tangible Shareholders Equity	$-422.53M
Shareholders Equity	$-422.53M
Common Shares Outstanding	71.04M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-161.77M
Cash Flow from Investing Activities	$-0.14M
Cash Flow from Financial Activities	$-0.19M
Beginning Cash	$300.12M
End Cash	$138.02M
Increase/Decrease in Cash	$-162.11M
Stock-Based Compensation	$23.11M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.23
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-0.96
Debt to Equity Ratio	-0.49
Gross Margin	87.50%
Operating Margin	-30.85%
EBIT Margin	-30.85%
EBITDA Margin	--
Pre-Tax Profit Margin	-60.55%
Profit Margin	-60.55%
Free Cash Flow	$-161.92M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.21
Inventory Turnover	1.71
Receiveable Turnover	0.89
Days Sales in Receivables	101.43
Return on Equity	7.09%
Return on Tangible Equity	7.09%
Return on Assets	-12.47%
Return on Investments	13.91%
Book Value Per Share	$-5.95
Free Cash Flow per Share	$-2.21
Operating Cash Flow per Share	$-2.20

Data from Zacks Investment Research, Inc.